Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Targeted Sequencing to Enhance, Liberate, and Optimize Treatment of Drug-resistant Tuberculosis

NCT05553236 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT05553236
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05553236 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Targeted Sequencing to Enhance, Liberate, and Optimize Treatment of Drug-resistant Tuberculosis
Lead sponsor
University of California, San Francisco
Phase
Not applicable
Overall status
Recruiting
Start date
August 1, 2024
Completion date
January 31, 2027
Enrollment
2,500 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cost-benefit analysis, drug-resistant tuberculosis, hiv coinfection